Raymond Furey - Mar 17, 2025 Form 4 Insider Report for RIGEL PHARMACEUTICALS INC (RIGL)

Role
EVP, GC, CCO & Corp Sec
Signature
/s/ Raymond Furey
Stock symbol
RIGL
Transactions as of
Mar 17, 2025
Transactions value $
$0
Form type
4
Date filed
3/19/2025, 08:55 PM
Previous filing
Feb 6, 2025
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction RIGL Employee Stock Option (right to buy) Award $0 +9.38K $0.00 9.38K Mar 17, 2025 Common Stock 9.38K $9.00 Direct F1, F2
transaction RIGL Employee Stock Option (right to buy) Award $0 +7.85K $0.00 7.85K Mar 17, 2025 Common Stock 7.85K $12.70 Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The Reporting Person was granted a stock option with a performance-based condition with respect to 9,375 shares of the Issuer's common stock on December 8, 2022, as adjusted for the one-for-ten reverse stock split effective June 27, 2024 (the "Reverse Stock Split"). The exercise price of this option is $9.00, which is the closing price of the Issuer's common stock on Nasdaq on the date of grant, as adjusted for the Reverse Stock Split. In light of the performance-based vesting condition, this grant was not reportable under Section 16 until the performance metric was satisfied. On March 17, 2025, it was determined that the performance metric had been met.
F2 The option was fully vested on March 17, 2025, the date the determination was made that the performance metric had been met.
F3 The Reporting Person was granted a stock option with a performance-based condition with respect to 7,850 shares of the Issuer's common stock on January 23, 2024, as adjusted for the Reverse Stock Split. The exercise price of this option is $12.70, which is the closing price of the Issuer's common stock on Nasdaq on the date of grant, as adjusted for the Reverse Stock Split. In light of the performance-based vesting condition, this grant was not reportable under Section 16 until the performance metric was satisfied. On March 17, 2025, it was determined that the performance metric had been met.